Abstract
From the carbolithiation of 6-morpholino fulvene (3) and different lithiated nitrogen containing heterocycles (2-N-methylimidazolyl, 2-N-(N,N-dimethylamino)methyl-imidazolyl, and 2-N-methylindolyl), the corresponding lithium cyclopentadienide intermediate (4a-c) was formed. These three lithiated intermediates underwent a transmetallation reaction with TiCl4 resulting in morpholino-functionalised titanocenes 5a-c. When these titanocenes were tested against LLC-PK cells, the IC50 values obtained were of 24, 36, and 41 μM respectively. The most cytotoxic titanocene in this paper (5a) with an IC50 value of 24 μM is found to be almost ten times less cytotoxic than cis-platin, which showed an IC50 value of 3.3 μM when tested on the epithelial pig kidney LLC-PK cell line, and approximately 2 times less cytotoxic than its dimethylamino-functionalised analogue. Encouragingly however, the IC50 value obtained for titanocene 5a is approximately 100 times better than titanocene dichloride itself.
Keywords: Anti-cancer drugs, cis-platin, titanocene, fulvene, morpholino-functionalised metallocenes, nitrogen containing heteroaryl-substituted metallocenes, RCC, LLC-PK
Medicinal Chemistry
Title: Synthesis and Cytotoxicity Studies of New Morpholino-Functionalised and N-Heteroaryl-Substituted Titanocene Anticancer Drugs
Volume: 4 Issue: 2
Author(s): M. Tacke, M. Hogan, J. Claffey and C. Pampillon
Affiliation:
Keywords: Anti-cancer drugs, cis-platin, titanocene, fulvene, morpholino-functionalised metallocenes, nitrogen containing heteroaryl-substituted metallocenes, RCC, LLC-PK
Abstract: From the carbolithiation of 6-morpholino fulvene (3) and different lithiated nitrogen containing heterocycles (2-N-methylimidazolyl, 2-N-(N,N-dimethylamino)methyl-imidazolyl, and 2-N-methylindolyl), the corresponding lithium cyclopentadienide intermediate (4a-c) was formed. These three lithiated intermediates underwent a transmetallation reaction with TiCl4 resulting in morpholino-functionalised titanocenes 5a-c. When these titanocenes were tested against LLC-PK cells, the IC50 values obtained were of 24, 36, and 41 μM respectively. The most cytotoxic titanocene in this paper (5a) with an IC50 value of 24 μM is found to be almost ten times less cytotoxic than cis-platin, which showed an IC50 value of 3.3 μM when tested on the epithelial pig kidney LLC-PK cell line, and approximately 2 times less cytotoxic than its dimethylamino-functionalised analogue. Encouragingly however, the IC50 value obtained for titanocene 5a is approximately 100 times better than titanocene dichloride itself.
Export Options
About this article
Cite this article as:
Tacke M., Hogan M., Claffey J. and Pampillon C., Synthesis and Cytotoxicity Studies of New Morpholino-Functionalised and N-Heteroaryl-Substituted Titanocene Anticancer Drugs, Medicinal Chemistry 2008; 4 (2) . https://dx.doi.org/10.2174/157340608783789202
DOI https://dx.doi.org/10.2174/157340608783789202 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Implication of CD154/CD40 Interaction in Healthy and Autoimmune Responses
Current Immunology Reviews (Discontinued) Targeting mTOR Signaling Pathway in Ovarian Cancer
Current Medicinal Chemistry Role of Liprins in the Regulation of Tumor Cell Motility and Invasion
Current Cancer Drug Targets Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update
Current Medicinal Chemistry Thalidomide Metabolism and Hydrolysis: Mechanisms and Implications
Current Drug Metabolism Cytochromes P450 and Skin Cancer: Role of Local Endocrine Pathways
Anti-Cancer Agents in Medicinal Chemistry Angiotensin-I Converting Enzyme Inhibitors as Potential Anti-Angiogenic Agents for Cancer Therapy
Current Cancer Drug Targets Old Drugs-Current Perspectives
Current Pharmacogenomics The Effects of Cantharidin and Cantharidin Derivates on Tumour Cells
Anti-Cancer Agents in Medicinal Chemistry New Direct and Frontal Tissue Acquisition Tools for Gene Expression Analysis in Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Mechanisms of Drug Resistance in Cancer Chemotherapy: Coordinated Role and Regulation of Efflux Transporters and Metabolizing Enzymes
Current Pharmaceutical Design Conventional Chemotherapy and Emerging Targeted Therapy for Advanced Adrenocortical Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Prevention of Intracerebral Haemorrhage
Current Drug Targets Cubilin, the Intrinsic Factor-Vitamin B12 Receptor in Development and Disease
Current Medicinal Chemistry Recent Patents and Patent Applications Relating to mTOR Pathway
Recent Patents on DNA & Gene Sequences Small Molecules for Immunomodulation in Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect
Current Drug Targets Targeting Vascular Niche by Parathyroid Hormone
Current Medicinal Chemistry Adrenomedullin and Nitric Oxide: Implications for the Etiology and Treatment of Primary Brain Tumors
CNS & Neurological Disorders - Drug Targets Molecular and Biochemical Changes of the Cardiovascular System due to Smoking Exposure
Current Pharmaceutical Design